11/10/2006

Aesku.Diagnostics GmbH

New AESKULISA assays for the US market

With FDA approval, now new assays from the unique AESKULISA® product line with maximum specificity and sensitivity are at hand for in vitro diagnostic use in the US. Same protocol, ready to use reagents, short incubation times – every new assay shares all the benefits that established the AESKULISA® product line as an ideal partner for laboratory automation systems.

AESKULISA® Gliadin-A and Gliadin-G for the combined or separate quantitative and qualitative determination of IgG antibodies to alpha gliadin in human serum complete AESKU.DIAGNOSTIC´S portfolio for the diagnosis of celiac disease.

Recently AESKU.DIAGNOSTICS also received FDA approval for to assays for a secure diagnosis of Cohn’s Disease and differentiation of from Colitis ulcerosa: AESKULISA® ASCA-A and ASCA-G for the quantitative and qualitative determination of IgA and IgG antibodies to cell wall proteoglycans of Saccharomyces cerevisiae in human serum.

Numerous products from the wide AESKULISA® product portfolio from the fields of rheumatology, thyroid, vasculitis, thrombosis, hepatology and gastroenterology are available in the U.S. market for in-vitro diagnostic use: ANA HEp-2, ANA-8Pro, ENA-6Pro, SS-A, SS-B, Scl-70, CenpB, Jo-1, U1-70, Sm, snRNP-C, dsDNA-G, ENA 6S, Cardiolipin A, Cardiolipin GM, Cardiolipin Check, tTg-A, tTg-G, Glia-G, Glia-A, ASCA-A and ASCA-G.

The whole AESKULISA® product line is of course available for research purposes.